2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-ControlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse events
2024
O-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results
Pellicer A, Taylor H, Alberich-Bayaari Á, Liu Y, Gamborg M, Barletta K, Heiser P, Pinton P, Bagger Y. O-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results. Human Reproduction 2024, 39: deae108.021. DOI: 10.1093/humrep/deae108.021.Peer-Reviewed Original ResearchDeep infiltrating endometriosisMagnetic resonance imagingVaginal ringLesion regressionImaging biomarkersLesion sizeAdverse eventsFractional volume of extravascular extracellular spaceAssociated with chronic pelvic painPlacebo-controlled phase 2 trialAdvanced stages of endometriosisVolume of extravascular extracellular spaceDopamine D2 receptor agonistLesion burdenTreatment efficacyGroup compared to placeboSeverity of adverse eventsDIE groupPlacebo vaginal ringChronic pelvic painD2 receptor agonistLesion typePhase 2 trialStages of endometriosisCompared to placebo
2018
166 Efficacy and Safety of Elagolix in a Subgroup of Women with Uterine Fibroids and Adenomyosis: Results from a Phase 2 Trial
Taylor H, Bedaiwy M, Lukes A, Chwalisz K, Owens C, Bradley L. 166 Efficacy and Safety of Elagolix in a Subgroup of Women with Uterine Fibroids and Adenomyosis: Results from a Phase 2 Trial. Journal Of Minimally Invasive Gynecology 2018, 25: s86-s87. DOI: 10.1016/j.jmig.2018.09.175.Peer-Reviewed Original ResearchEfficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial
Taylor H, Bedaiwy M, Lukes A, Chwalisz K, Owens C, Bradley L. Efficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial. Fertility And Sterility 2018, 110: e61. DOI: 10.1016/j.fertnstert.2018.07.186.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply